MitraClip European approval
This article was originally published in The Gray Sheet
Executive Summary
Evalve's MitraClip percutaneous mitral valve repair system gains CE mark approval, the firm announces March 25. Evalve says it is the first commercially available device for nonsurgical treatment of mitral regurgitation. The randomized arm of a multi-center pivotal trial for U.S. approval (EVEREST) is expected to complete enrollment by the end of the year